<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Deals and M&amp;A</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>‘Disciplined’ $665M deal moves Oscotec’s cevidoplenib to Agios  </title>
      <description>
        <![CDATA[Agios Pharmaceuticals Inc.’s potential $665 million deal for Oscotec Inc.’s cevidoplenib, a phase III-ready oral SYK inhibitor to treat immune thrombocytopenia, marks a new chapter of development focused on cancer therapy resistance for Oscotec, CEO Yoon Tae-young said.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731632</guid>
      <pubDate>Fri, 05 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731632-disciplined-665m-deal-moves-oscotecs-cevidoplenib-to-agios</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-handshake-with-coin-chart-background.webp?t=1704408549" type="image/jpeg" medium="image" fileSize="317806">
        <media:title type="plain">Deal handshake with coin, chart background</media:title>
      </media:content>
    </item>
    <item>
      <title>Cytomx, Regeneron expand bispecifics deal to potential $4B</title>
      <description>
        <![CDATA[Cytomx Therapeutics Inc. and Regeneron Pharmaceuticals Inc., which inked a bispecifics-focused collaboration worth up to $2 billion in 2022, agreed to broaden their efforts in an expanded deal that provides Cytomx with additional funding up front as it advances its promising colorectal cancer candidate, varsetatug masetecan (Varseta-M), and fills the gap left by the recently terminated agreement with Astellas Pharma Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731540</guid>
      <pubDate>Wed, 03 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731540-cytomx-regeneron-expand-bispecifics-deal-to-potential-4b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Digital-handshake.webp?t=1683126686" type="image/jpeg" medium="image" fileSize="453851">
        <media:title type="plain">Digital handshake </media:title>
      </media:content>
    </item>
    <item>
      <title>Lilly enters $1.9B kidney disease deal for Ascidian’s exon editors</title>
      <description>
        <![CDATA[Once again, Eli Lilly and Co. has signed a billion-dollar deal, this time with Boston-based Ascidian Therapeutics Inc., a company that is barely four years old and one that is focused on treating human diseases by rewriting RNA. “Our technology, we call it RNA exon editing,” said Ascidian Chief Scientific Officer Robert Bell. “It edits RNA, not DNA … but it does so at the kilobase scale.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/731539</guid>
      <pubDate>Wed, 03 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731539-lilly-enters-19b-kidney-disease-deal-for-ascidians-exon-editors</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/RNA-3D-illustration.webp?t=1725482193" type="image/jpeg" medium="image" fileSize="212050">
        <media:title type="plain">3D illustration of RNA</media:title>
      </media:content>
    </item>
    <item>
      <title>BMS-Hengrui deal strikes panic in Washington</title>
      <description>
        <![CDATA[On the heels of the multibillion-dollar licensing deal between Bristol Myers Squibb Co. and Jiangsu Hengrui Pharmaceuticals Co. Ltd., Chairman John Moolenaar (R-MI), of the House Select Committee on the Chinese Communist Party, sent a letter to Treasury Secretary Scott Bessent urging him to add biotechnology as a prohibited technology under the Comprehensive Outbound Investment National Security (COINS) Act of 2025.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731649</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731649-bms-hengrui-deal-strikes-panic-in-washington</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/US-capital-washington-congress-government.webp?t=1588689267" type="image/png" medium="image" fileSize="2212023">
        <media:title type="plain">U.S. Capitol building</media:title>
      </media:content>
    </item>
    <item>
      <title>Hanmi, Haisco win billion-dollar partnerships with Eli Lilly</title>
      <description>
        <![CDATA[Hanmi Pharmaceutical Co. Ltd. secured a $1.26 billion deal with Eli Lilly and Co. to out-license ex-Korea rights to sonefpeglutide (HM-15912), a Lapscovery-based glucagon-like peptide-2 analog in development for multiple indications, including an ongoing phase II study of short bowel syndrome. It was one of two billion-dollar Asian company deals signed by Lilly on June 1, with the second transaction involving Haisco Pharmaceutical Group Co. Ltd., of Beijing.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731645</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731645-hanmi-haisco-win-billion-dollar-partnerships-with-eli-lilly</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Hanmi-signage-6-1.webp?t=1780342948" type="image/jpeg" medium="image" fileSize="195343">
        <media:title type="plain">Hanmi signage</media:title>
        <media:description type="plain">Credit: Hanmi Pharmaceutical Co. Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal</title>
      <description>
        <![CDATA[Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early stage and de novo antibody-drug conjugates (ADCs) and multispecific antibodies for oncology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731644</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731644-adcs-multispecific-antibodies-anchor-10b-pfizer-innovent-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Antibodies-attacking-cancer-cell.webp?t=1621365766" type="image/png" medium="image" fileSize="566115">
        <media:title type="plain">Antibodies attacking cancer cell</media:title>
      </media:content>
    </item>
    <item>
      <title>China deals highlight biopharma evolution, reports LEK</title>
      <description>
        <![CDATA[In 2025, China’s outbound life sciences and biopharma deals reached nearly $100 billion, about 12 times the level seen in 2021, underscoring how quickly global appetite for Chinese assets has accelerated, according to a recent report by L.E.K. Consulting. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/731530</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731530-china-deals-highlight-biopharma-evolution-reports-lek</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-deals-illustration.webp?t=1780424261" type="image/jpeg" medium="image" fileSize="130740">
        <media:title type="plain">China map/flag with silhouettes of business people</media:title>
      </media:content>
    </item>
    <item>
      <title>Travere expands rare kidney portfolio in $1B+ Everest deal </title>
      <description>
        <![CDATA[Less than two months after winning FDA approval for a second indication for Filspari (sparsentan), Travere Therapeutics Inc. added to its rare kidney disease pipeline by exclusively licensing civorebrutinib from Everest Medicines Ltd. in a deal that could be worth more than $1.14 billion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731526</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731526-travere-expands-rare-kidney-portfolio-in-1b-everest-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Nephrology/Nephrology-Renal-Kidney.webp?t=1669825127" type="image/png" medium="image" fileSize="946164">
        <media:title type="plain">3D illustration of kidney cross section</media:title>
      </media:content>
    </item>
    <item>
      <title>Edgewise sells muscular dystrophy assets to Servier for $2.65B</title>
      <description>
        <![CDATA[Edgewise Therapeutics Inc. is pulling in $1.55 billion up front by selling its muscular dystrophy business, including its fast skeletal myosin inhibitor, sevasemten (EDG-5506), to Servier SA. The deal is potentially worth up to $2.65 billion when including a potential $1.1 billion in milestone payments.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731512</guid>
      <pubDate>Mon, 01 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731512-edgewise-sells-muscular-dystrophy-assets-to-servier-for-265b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Purple-pie-chart.webp?t=1706041689" type="image/jpeg" medium="image" fileSize="65416">
        <media:title type="plain">Purple pie chart </media:title>
      </media:content>
    </item>
    <item>
      <title>Hanmi, Haisco win billion-dollar partnerships with Eli Lilly</title>
      <description>
        <![CDATA[Hanmi Pharmaceutical Co. Ltd. secured a $1.26 billion deal with Eli Lilly and Co. to out-license ex-Korea rights to sonefpeglutide (HM-15912), a Lapscovery-based glucagon-like peptide-2 analog in development for multiple indications, including an ongoing phase II study of short bowel syndrome. It was one of two billion-dollar Asian company deals signed by Lilly on June 1, with the second transaction involving Haisco Pharmaceutical Group Co. Ltd., of Beijing.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731459</guid>
      <pubDate>Mon, 01 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731459-hanmi-haisco-win-billion-dollar-partnerships-with-eli-lilly</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Hanmi-signage-6-1.webp?t=1780342948" type="image/jpeg" medium="image" fileSize="195343">
        <media:title type="plain">Hanmi signage</media:title>
        <media:description type="plain">Credit: Hanmi Pharmaceutical Co. Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal</title>
      <description>
        <![CDATA[Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early stage and de novo antibody-drug conjugates (ADCs) and multispecific antibodies for oncology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731458</guid>
      <pubDate>Fri, 29 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731458-adcs-multispecific-antibodies-anchor-10b-pfizer-innovent-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Antibodies-attacking-cancer-cell.webp?t=1621365766" type="image/png" medium="image" fileSize="566115">
        <media:title type="plain">Antibodies attacking cancer cell</media:title>
      </media:content>
    </item>
    <item>
      <title>BMS-Hengrui deal strikes panic in Washington</title>
      <description>
        <![CDATA[On the heels of the multibillion-dollar licensing deal between Bristol Myers Squibb Co. and Jiangsu Hengrui Pharmaceuticals Co. Ltd., Chairman John Moolenaar (R-MI), of the House Select Committee on the Chinese Communist Party, sent a letter to Treasury Secretary Scott Bessent urging him to add biotechnology as a prohibited technology under the Comprehensive Outbound Investment National Security (COINS) Act of 2025.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731574</guid>
      <pubDate>Fri, 29 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731574-bms-hengrui-deal-strikes-panic-in-washington</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/US-capital-washington-congress-government.webp?t=1588689267" type="image/png" medium="image" fileSize="2212023">
        <media:title type="plain">U.S. Capitol building</media:title>
      </media:content>
    </item>
    <item>
      <title>BMS-Hengrui deal strikes panic in Washington</title>
      <description>
        <![CDATA[On the heels of the multibillion-dollar licensing deal between Bristol Myers Squibb Co. and Jiangsu Hengrui Pharmaceuticals Co. Ltd., Chairman John Moolenaar (R-MI), of the House Select Committee on the Chinese Communist Party, sent a letter to Treasury Secretary Scott Bessent urging him to add biotechnology as a prohibited technology under the Comprehensive Outbound Investment National Security (COINS) Act of 2025.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731422</guid>
      <pubDate>Wed, 27 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731422-bms-hengrui-deal-strikes-panic-in-washington</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/US-capital-washington-congress-government.webp?t=1588689267" type="image/png" medium="image" fileSize="2212023">
        <media:title type="plain">U.S. Capitol building</media:title>
      </media:content>
    </item>
    <item>
      <title>Eli Lilly offers to buy three vaccine makers</title>
      <description>
        <![CDATA[Eli Lilly and Co. has offered to buy three vaccine companies for up to $3.8 billion combined, including up to $1.55 billion for Vaccine Company Inc., whose in vivo nanoparticle (IVN) technologies are designed to enable antigens that elicit durable immune responses, much like virus-like particle (VLP) vaccines, but avoid the VLP manufacturing burden.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731290</guid>
      <pubDate>Wed, 27 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731290-eli-lilly-offers-to-buy-three-vaccine-makers</link>
    </item>
    <item>
      <title>Medtronic bolsters pain portfolio in $650M SPR Therapeutics buy </title>
      <description>
        <![CDATA[Medtronic plc is strengthening its pain management portfolio with its $650 million move to buy SPR Therapeutics Inc. and bring the company’s peripheral nerve stimulation system for sustained pain relief into its neuromodulation offering. The deal marks Medtronic’s third tuck-in deal so far this year, following its $585 million purchase of Cathworks Ltd. and $550 million acquisition of Scientia Vascular Inc., and is also a sign of the momentum in M&A activity in the medtech sector with other players making strategic acquisitions.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731402</guid>
      <pubDate>Tue, 26 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731402-medtronic-bolsters-pain-portfolio-in-650m-spr-therapeutics-buy</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/SPRINT-Device-Image_4clr-8.22.webp?t=1779820058" type="image/jpeg" medium="image" fileSize="65780">
        <media:title type="plain">SPR Therapeutic Inc.’s Sprint PNS system</media:title>
        <media:description type="plain">Sprint PNS system. Credit: SPR Therapeutics Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Lilly buys three vaccine makers; PCSK9 base editor shows promise</title>
      <description>
        <![CDATA[As the most active biopharma acquirer of 2026, Eli Lilly and Co. offered to buy three vaccine companies for up to $3.8 billion combined, while it simultaneously released positive early clinical results of a gene editing medicine brought into the fold last year through its buyout of Verve Therapeutics Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731401</guid>
      <pubDate>Tue, 26 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731401-lilly-buys-three-vaccine-makers-pcsk9-base-editor-shows-promise</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Syringes-in-virus-cell-company-logos.webp?t=1779831670" type="image/png" medium="image" fileSize="273178">
        <media:title type="plain">Syringes in virus cell; Lilly, Curevo, Limmatech, Vaccine Company   logos</media:title>
      </media:content>
    </item>
    <item>
      <title>Daewoong takes over Turn Bio’s longevity platform from Hanall</title>
      <description>
        <![CDATA[Daewoong Pharmaceutical Co. Ltd. announced after South Korean market hours May 21 that it gained successive rights to Turn Biotechnologies Inc.’s mRNA-based cellular rejuvenation platform from Hanall Biopharma Co. Ltd.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731469</guid>
      <pubDate>Tue, 26 May 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731469-daewoong-takes-over-turn-bios-longevity-platform-from-hanall</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-aging-time.webp?t=1693406596" type="image/jpeg" medium="image" fileSize="349155">
        <media:title type="plain">DNA double helix with sand hour glass</media:title>
      </media:content>
    </item>
    <item>
      <title>Hengrui, BMS deal watershed moment for China biotech  </title>
      <description>
        <![CDATA[The recent multibillion-dollar licensing alliance between Bristol Myers Squibb Co. and Jiangsu Hengrui Pharmaceuticals Co. Ltd is not an outlier, but rather the clearest sign yet that China’s biotech industry has entered a new phase of global influence.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731467</guid>
      <pubDate>Tue, 26 May 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731467-hengrui-bms-deal-watershed-moment-for-china-biotech</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/Chinese-flag-and-microscopes.webp?t=1594666411" type="image/png" medium="image" fileSize="472941">
        <media:title type="plain">Chinese flag and microscopes</media:title>
      </media:content>
    </item>
    <item>
      <title>Daewoong takes over Turn Bio’s longevity platform from Hanall</title>
      <description>
        <![CDATA[Daewoong Pharmaceutical Co. Ltd. announced after South Korean market hours May 21 that it gained successive rights to Turn Biotechnologies Inc.’s mRNA-based cellular rejuvenation platform from Hanall Biopharma Co. Ltd.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731389</guid>
      <pubDate>Fri, 22 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731389-daewoong-takes-over-turn-bios-longevity-platform-from-hanall</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-aging-time.webp?t=1693406596" type="image/jpeg" medium="image" fileSize="349155">
        <media:title type="plain">DNA double helix with sand hour glass</media:title>
      </media:content>
    </item>
    <item>
      <title>Hengrui, BMS deal watershed moment for China biotech  </title>
      <description>
        <![CDATA[The recent multibillion-dollar licensing alliance between Bristol Myers Squibb Co. and Jiangsu Hengrui Pharmaceuticals Co. Ltd is not an outlier, but rather the clearest sign yet that China’s biotech industry has entered a new phase of global influence.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731341</guid>
      <pubDate>Wed, 20 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731341-hengrui-bms-deal-watershed-moment-for-china-biotech</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/Chinese-flag-and-microscopes.webp?t=1594666411" type="image/png" medium="image" fileSize="472941">
        <media:title type="plain">Chinese flag and microscopes</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma deal and M&amp;A values soar in early 2026 </title>
      <description>
        <![CDATA[Biopharma deal value through the first four months of 2026 reached $92.98 billion, outpacing every recent year and running well ahead of 2025’s strong $79.82 billion over the same period. January and February each cleared $30 billion, while March and April totaled $18.05 billion and $13.3 billion, respectively.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731368</guid>
      <pubDate>Tue, 19 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731368-biopharma-deal-and-m-and-a-values-soar-in-early-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/DNA-with-bar-chart.webp?t=1707510184" type="image/jpeg" medium="image" fileSize="103185">
        <media:title type="plain">DNA with bar chart</media:title>
      </media:content>
    </item>
    <item>
      <title>Daewoong nabs Innovo’s preclinical IBD asset in ₩663B deal</title>
      <description>
        <![CDATA[Daewoong Pharmaceutical Co. Ltd. secured an exclusive license to Innovo Therapeutics Inc.’s INV-008, a novel oral 15-hydroxyprostaglandin dehydrogenase inhibitor for inflammatory bowel disease (IBD), through a potential ₩662.5 billion (US$443.6 million) deal. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/731364</guid>
      <pubDate>Tue, 19 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731364-daewoong-nabs-innovos-preclinical-ibd-asset-in-663b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Daewoong-Innovo-CEOs-5-13.webp?t=1778686979" type="image/jpeg" medium="image" fileSize="116766">
        <media:title type="plain">Daewong CEO Park Sung-soo (left) with Innovo CEO Park Hee-dong</media:title>
        <media:description type="plain">Daewong Pharmaceutical CEO Park Sung-soo (left) with Innovo Therapeutics CEO Park Hee-dong.</media:description>
      </media:content>
    </item>
    <item>
      <title>Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal </title>
      <description>
        <![CDATA[Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage Alzheimer’s disease (AD) therapy, AR-1001. The option fee plus license agreement has potential to tally $4.7 billion for Aribio, marking the largest deal for an AD asset inked by a Korean biotech company.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731362</guid>
      <pubDate>Tue, 19 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731362-fosun-secures-rights-to-aribios-ar-1001-in-potential-47b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-illustration.webp?t=1755091469" type="image/png" medium="image" fileSize="522090">
        <media:title type="plain">Doctor with brain illustration, businessman with dollar sign illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Med-tech M&amp;A’s blockbuster streak continues with $19B April value  </title>
      <description>
        <![CDATA[Med-tech M&A value through the first four months of 2026 reached $62.01 billion, the highest total for the period since 2022’s $73.58 billion and a dramatic step up from 2025’s $20.03 billion and 2024’s $5.74 billion over the same period.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731315</guid>
      <pubDate>Mon, 18 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731315-med-tech-m-and-as-blockbuster-streak-continues-with-19b-april-value</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Handshake-with-dollar-sign-and-checkmark.webp?t=1684784189" type="image/jpeg" medium="image" fileSize="89282">
        <media:title type="plain">Handshake with dollar sign and checkmark</media:title>
      </media:content>
    </item>
    <item>
      <title>Boston Sci invests $1.5B in Mirus, gains option for TAVR system </title>
      <description>
        <![CDATA[Boston Scientific Corp. has invested $1.5 billion for a 34% equity stake in Mirus LLC in a deal under which it is also gaining an exclusive option to acquire the Siegel balloon expandable transcatheter aortic valve replacement (TAVR) system.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731314</guid>
      <pubDate>Mon, 18 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731314-boston-sci-invests-15b-in-mirus-gains-option-for-tavr-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Mirus-Siegel-TAVR-5-18.webp?t=1779132172" type="image/jpeg" medium="image" fileSize="79457">
        <media:title type="plain">Mirus Siegel TAVR</media:title>
        <media:description type="plain">Siegel balloon expandable TAVR) system. Credit: Mirus LLC</media:description>
      </media:content>
    </item>
    <item>
      <title>Regeneron’s fianlimab lags in melanoma, does $2.3B deal with Parabilis</title>
      <description>
        <![CDATA[Regeneron Pharmaceuticals Inc. stuck with the tradition of releasing bad news on Friday afternoon and good news on Monday morning with a pair of announcements bracketing the weekend. On May 15, 2026, the Tarrytown, N.Y.-based company announced disappointing data for its LAG-3 inhibitor fianlimab. And then on May 18, 2026, Regeneron announced better news in the form of a deal with Parabilis Medicines Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731310</guid>
      <pubDate>Mon, 18 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731310-regenerons-fianlimab-lags-in-melanoma-does-23b-deal-with-parabilis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Skin-through-magnifier.webp?t=1779138264" type="image/jpeg" medium="image" fileSize="144818">
        <media:title type="plain">Skin through magnifier</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma deal and M&amp;A values soar in early 2026 </title>
      <description>
        <![CDATA[Biopharma deal value through the first four months of 2026 reached $92.98 billion, outpacing every recent year and running well ahead of 2025’s strong $79.82 billion over the same period. January and February each cleared $30 billion, while March and April totaled $18.05 billion and $13.3 billion, respectively.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731212</guid>
      <pubDate>Fri, 15 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731212-biopharma-deal-and-m-and-a-values-soar-in-early-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/DNA-with-bar-chart.webp?t=1707510184" type="image/jpeg" medium="image" fileSize="103185">
        <media:title type="plain">DNA with bar chart</media:title>
      </media:content>
    </item>
    <item>
      <title>Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal </title>
      <description>
        <![CDATA[Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage Alzheimer’s disease (AD) therapy, AR-1001. The option fee plus license agreement has potential to tally $4.7 billion for Aribio, marking the largest deal for an AD asset inked by a Korean biotech company.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731194</guid>
      <pubDate>Thu, 14 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731194-fosun-secures-rights-to-aribios-ar-1001-in-potential-47b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-illustration.webp?t=1755091469" type="image/png" medium="image" fileSize="522090">
        <media:title type="plain">Doctor with brain illustration, businessman with dollar sign illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal</title>
      <description>
        <![CDATA[In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early development programs in the fields of oncology, hematology and immunology. Shanghai-based Hengrui will hold exclusive rights in mainland China, Hong Kong and Macau, while Princeton, N.J.-based BMS will hold exclusive rights in the rest of the world. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/731267</guid>
      <pubDate>Thu, 14 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731267-advancing-the-best-of-both-bms-hengrui-enter-152b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Drug-research-illustration2.webp?t=1642547340" type="image/png" medium="image" fileSize="473295">
        <media:title type="plain">Test tubes, dropper and capsules</media:title>
      </media:content>
    </item>
    <item>
      <title>Daewoong nabs Innovo’s preclinical IBD asset in ₩663B deal</title>
      <description>
        <![CDATA[Daewoong Pharmaceutical Co. Ltd. secured an exclusive license to Innovo Therapeutics Inc.’s INV-008, a novel oral 15-hydroxyprostaglandin dehydrogenase inhibitor for inflammatory bowel disease (IBD), through a potential ₩662.5 billion (US$443.6 million) deal. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/731063</guid>
      <pubDate>Wed, 13 May 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731063-daewoong-nabs-innovos-preclinical-ibd-asset-in-663b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Daewoong-Innovo-CEOs-5-13.webp?t=1778686979" type="image/jpeg" medium="image" fileSize="116766">
        <media:title type="plain">Daewong CEO Park Sung-soo (left) with Innovo CEO Park Hee-dong</media:title>
        <media:description type="plain">Daewong Pharmaceutical CEO Park Sung-soo (left) with Innovo Therapeutics CEO Park Hee-dong.</media:description>
      </media:content>
    </item>
  </channel>
</rss>
